Triple-Drug attack before lung surgery shows promise in early trial
NCT ID NCT07567326
First seen May 06, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa plus recaticimab and chemo, then undergo surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab or retlirafusp alfa (SHR-1701) plus recaticimab and chemotherapy
What this could lead to
If successful, this combination could improve the chance of eliminating all cancer before surgery and potentially extend survival for people with resectable non-small cell lung cancer.
What could go wrong
This is an early phase 2 trial with only 78 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects, and the benefit over standard treatment is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.